Yup, looked at LJPC very closely, mostly relating to lupus and stroke/miscarriage.
There are excellent research programs designed to provide pig organs that do not express the epitope responsible for antibody binding, including one at a division of Novartis (Imutran, the BTRN collaborator). There are also complement inhibitors in development. The recent description of engineered hosts and the BTRN method of absorption are alternative approaches (that I don't like). The LJPC approach is therefore rather complex and risky, IMO. Perhaps I should say rather complex and very risky..... not one chance in hell.
I do not consider it to be completely crazy to be looking for passive inhibitors that interfere with the binding of antibody. If the LJPC effort points in that direction, then.... still sort of nuts, given efforts to secure pig organs that do not express the antigen.
>> My intuition is that the large share orders were scooped
up by the market maker,who then,working with a thin float,was able to raise the the
bid and ask for us retail suckers <<
Don't think so.
I'm preparing a brief report (general outline, technical approaches, etc...... no investment advice or rating) on BTRN for BioPlatform, Inc. If anyone is interested in it, please leave a PM for John Metcalf......
exchange2000.com
|
